Standout Papers
Immediate Impact
64 standout
Citing Papers
Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements
2024 Standout
Tumor biomarkers for diagnosis, prognosis and targeted therapy
2024 Standout
Works of Jiaru Bai being referenced
Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma
2020
Evaluating the cost-effectiveness of current FDA-approved PARP inhibitors for the treatment of recurrent ovarian cancer.
2017
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Jiaru Bai | 354 | 141 | 411 | 203 | 21 | 625 | |
| David R. Keith | 91 | 44 | 358 | 164 | 26 | 622 | |
| Kaitlin Daniels | 480 | 172 | 518 | 224 | 10 | 679 | |
| Jonathan D. Hall | 190 | 12 | 399 | 395 | 24 | 645 | |
| Göran Smith | 290 | 56 | 500 | 359 | 31 | 680 | |
| Jiayi Joey Yu | 194 | 222 | 230 | 100 | 25 | 726 | |
| Martin Zaltz Austwick | 89 | 29 | 179 | 313 | 23 | 723 | |
| Zhu Han | 177 | 75 | 252 | 92 | 35 | 614 | |
| Elena Belavina | 218 | 175 | 136 | 133 | 19 | 634 | |
| Upender Subramanian | 380 | 181 | 183 | 77 | 21 | 552 | |
| Judd Cramer | 331 | 59 | 374 | 218 | 7 | 660 |
All Works
Login with ORCID to disown or claim papers
Loading papers...